Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 985 across all filing types
Latest filing 2018-01-22 Director's Dealing
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
FORM 3 -
Director's Dealing
2018-01-22 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 8, 2018. It includes a Regulation FD Disclosure indicating that attached slides will be presented at the J.P. Morgan Healthcare Conference. The document references a presentation (Exhibit 99.1) but does not contain detailed financial statements or analysis itself. The length is 2948 characters, which is relatively short and consistent with an announcement rather than a full report. The content is primarily an announcement of an investor presentation event and the attached presentation slides. Therefore, this filing is best classified as an Investor Presentation (IP).
2018-01-08 English
FORM 4 -
Director's Dealing
2018-01-04 English
FORM 4 -
Director's Dealing
2018-01-04 English
FORM 4 -
Director's Dealing
2018-01-04 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 3, 2018, by OvaScience, Inc. It reports on a corporate restructuring involving workforce reduction and the appointment of a new Chief Scientific Officer. The document includes details about the new hire's compensation and stock options, as well as a press release attached as an exhibit. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The content primarily concerns management changes and organizational updates. Therefore, the document fits the category of Board/Management Information (MANG). The document length (9691 characters) is sufficient to contain substantive information, not just an announcement of a report. Hence, the classification is MANG with high confidence.
2018-01-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.